ID: MRFR/HC/6261-CR | February 2021 | Region: Global | 196 pages
According to MRFR, the Epilepsy Market is slated to acquire USD 9.50 Billion valuation by 2023, exhibiting a CAGR of 8.20% over the assessment period (2018-2023). The increasing rate of epilepsy prevalence in the geriatric community and the rise in accident-induced brain injury cases are major factors driving market growth.
The new coronavirus has spread worldwide in a relatively short period and has become a pandemic. Many affected patients have symptoms such as dry cough, tiredness, dyspnea, and fever. However, the infection with Covid-19 disrupts multiple tissues, including the kidney, liver, and nervous system. Common neurological symptoms of Covid-19 infection include delirium, depression, fever, and loss of smell and taste. It can cause stroke and epilepsy in rare cases. This has risen the demand for efficient epilepsy cures and medications. Moreover, the growing R&D investments towards COVID 19 treatments may also contribute towards the epilepsy market growth.
Increasing Incidence of PTE to Drive Market Growth
The high sensitivity risk of elderly epilepsy is expected to fuel consumer demand. In addition, brain damage that can cause post-traumatic epilepsy (PTE) and post-traumatic seizures (PTS) can fuel demand in the epilepsy industry. The worldwide demand for epilepsy is also influenced epilepsy market by primary factors such as developing experimental medicines, the arrival of new drugs in developed regions and the prevalence of neurological disorders such as meningitis and tumors. This rise is further fueled by an improvement in healthcare prices and an increase in disposable income.
Growing Adoption Of Advanced Imaging Technology For Early Diagnosis Contributes To Market Growth
Emerging trends such as businesses focused on designing innovative treatments for refractory epilepsy and doctors requiring higher effectiveness medications is increasing the R&D investments towards the epilepsy market. The growing adoption of rational polytherapy and the advanced imaging technology for early diagnosis also contributes to market growth. Moreover, the adoption of advanced digital healthcare models such as mHealth and telemedicine is likely to create growth opportunities for the epilepsy market.
Rise in Medication Costs Likely to Impede Market Growth
On the other hand, the demand expansion is hampered by a time-consuming prescription approval process, and rising medication costs. Moreover, the low awareness about the challenges of epilepsy can also hinder the epilepsy market growth. Infact, consumers are increasingly petitioning gaming companies and social media platforms to include epileptic warnings.
The research report segments the global market for epilepsy by disorder, diagnosis & care and end-use.
By condition, the epilepsy market is bifurcated into epilepsy drug-resistant/intractable epilepsy and others. The drug-resistant epilepsy segment is expected to hit a value of USD 2.93 billion by the end of the forecast period. The advent of rational polytherapy for treating disease with minimal side-effects is expected to produce substantial revenue for the epilepsy market.
By Diagnosis and Treatment
By diagnosis and treatment, the epilepsy market for epilepsy is segmented into diagnosis and treatment. The treatment category is expected to drive the epilepsy market at a 7.91 percent CAGR during the projected period due to the availability of inexpensive medications to treat partial epileptic seizures. In addition, the approval of successful drugs by regulatory authorities will promote the development of the segment. On the other hand, the diagnostic segment is expected to mature at 8.76 percent CAGR over the evaluation period. The use of numerous imaging tests and blood tests to diagnose early on the condition is expected to accelerate segment development tenfold.
Based on the end-users, the epilepsy market is segmented into hospitals, clinics, diagnostic centers, ambulatory surgical centers, and others. The hospital segment is touted to dominate the market growth over the review period, followed by the clinics segment. Moreover, hospitals that encourage the procurement of medicine from hospital premises are likely to promote the market.
The epilepsy industry in the region is segmented into the Americas, Europe, Asia Pacific (APAC) and the Middle East and Africa (MEA).
North America Dominates the Market with Superior Healthcare Infrastructure
Among them, the Americas accounted for 41 percent of the share in 2017, led by Europe, APAC, and MEA. North America is a leading contributor to the market due to the availability of well-established healthcare facilities, beneficial government policies aimed at strengthening the healthcare sector, and the presence of substantial research and development programs.
Growing R&D Investments Drive the Europe Market
Europe is expected to have a CAGR of 8.31% over the projected period. Increased investment in research and production of successful medications to cure epilepsy coupled with a high prevalence of the disease is expected to fuel regional demand exponentially.
Development of Novel Drugs to Raise APAC Market Scope
The APAC epilepsy market is set to reach a value of USD 2.04 million by 2023 due to the high occurrence of condition reported in the country. Also, the countries of India, South Korea and China, which are emerging as viable destinations for researching and producing novel products, will stimulate consumer demand over the forecast period.
Production of efficient drugs and rising product approvals to be the primary tactics adopted by leading players
Companies active in the epilepsy therapeutics industry plan to strengthen their global reach through authorization by government agencies, partnerships, strategic mergers & acquisitions with other epilepsy market leaders in their respective territories and regions around the world. In order to strengthen their position in the global market for epilepsy therapeutics, robust progressive research and development efforts and product pipelines and growing product approvals are crucial strategies followed by these players. To increase their market share, most of the major players are engaged in reinforcing their product portfolio. It is predicted that the launch of new medicines would facilitate the market expansion of anti-epileptic medication.
December 2020: European CNS Specialist acquired Medinutrix Ltd to provide an immediate platform for the recently acquired market-leading epilepsy treatment 'Buccolam' in Ireland.
LivaNova PLC (U.K.)
GlaxoSmithKline PLC (U.K.)
Eisai Co. Ltd. (Japan)
Pfizer Inc. (U.S.)
Medtronic PLC (Ireland)
UCB SA (Belgium)
NeuroPace Inc. (U.S.)
GW Pharmaceuticals PLC (U.K.)
Novartis AG (Switzerland)
Johnson & Johnson Services Inc. (U.S.)
Abbott Laboratories (U.S.)
December 2020: The testing of Cenobamate (Xcopri), a new epilepsy drug showed positive results, where an open-label trial found that the incidence of seizures was substantially decreased and that among 240 adult patients who obtained cenobamate, the seizure-freedom rate was significantly increased. The use of concomitant antiseizure drugs (ASMs) by patients was also limited, with little effect on effectiveness.
December 2020: A new, less invasive epilepsy laser surgery, dubbed LITT or laser interstitial thermal therapy, was proposed by the University of Alabama at Birmingham (UAB). For certain forms of epilepsy, it is a new technique to use a laser to destroy brain tissue that is causing seizures.
This report focuses on the growth of the global epilepsy therapeutics market and consists of an extensive executive summary, including a market snapshot that includes details about different segments of the market. It also offers an overview of market competitiveness in terms of geography and market share analysis by leading participants, providing a detailed analysis of the overall competitive situation emerging in the epilepsy therapeutic market. The study also offers knowledge and data analyses of the global market for its commodity, distribution channel, and regional segments.
Epilepsy Drug Resistant/Intractable Epilepsy
By Diagnosis and Treatment
Ambulatory Surgical Centers
|Market Size||USD 9.50 Billion|
|Forecast Units||Value (USD Billion)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Condition, Diagnosis & Treatment and End-use|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||LivaNova PLC (U.K.), GlaxoSmithKline PLC (U.K.), Eisai Co. Ltd. (Japan), Pfizer Inc. (U.S.), Medtronic PLC (Ireland), UCB SA (Belgium), NeuroPace Inc. (U.S.), GW Pharmaceuticals PLC (U.K.), Novartis AG (Switzerland), Johnson & Johnson Services Inc. (U.S.), Abbott Laboratories (U.S.)|
|Key Market Opportunities||Growing Adoption Of Advanced Imaging Technology For Early Diagnosis|
|Key Market Drivers||Increasing Incidence of PTE to Drive Market Growth|
Frequently Asked Questions (FAQ) :
Epilepsy market is projected to grow at an 8.20% CAGR between 2020-2027.
The Americas is expected to dominate the epilepsy market.
Epilepsy market is predicted to touch USD 9,509.2 million by 2023.
Rising cases of brain injuries and prevalence of epilepsy among the older generation are the key factors driving the epilepsy market.
Hospitals will dominate the epilepsy market.
This table of content is tentative and subject to change as the research progresses.
Please Note: Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.